CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.
Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Tisa-cel 和 cilta-cel 分别在 LBCL 和 MM 患者中显示出更有利的 ICANS 安全性特征，而 brexu-cel 在 MCL 患者中显示出更高的 ICANS 发生率。需要进一步的比较研究来校正治疗相关的混杂因素。
嵌合抗原受体（CAR）T细胞疗法是一种过继性免疫疗法，已扩大了多种血液系统恶性肿瘤的治疗选择。然而，CAR-T 疗法与一系列副作用相关，包括免疫效应细胞相关神经毒性综合征（ICANS），其发生率和严重程度不一。
评估CAR-T 治疗在不同血液疾病中ICANS的发生率和特征，重点关注产品特异性差异。
我们检索了PubMed、Embase和Cochrane Library，截止日期为2024年2月16日。通过随机效应模型估计了ICANS（总体、较严重和较轻）的合并发生率及95%置信区间（CIs）。针对每种淋巴瘤类型——大B细胞淋巴瘤（LBCL）、多发性骨髓瘤（MM）和套细胞淋巴瘤（MCL）——分别进行了meta分析。
在回顾的259篇文章中，对30项研究进行了meta分析。在LBCL患者中，tisagenlecleucel的ICANS发生率（16.5 %，95 % CI：12.9-20.9；n = 1108例患者）似乎低于axicabtagene ciloleucel（45.6 %，95 % CI：39.6-51.7；n = 1579）。在MM患者中，ciltacabtagene autoleucel的发生率（10.4 %，95 % CI：5.2-19.9；n = 348）似乎低于idecabtagene vicleucel（18.3 %；95 % CI：15.4-21.5；n = 631）。对于MCL患者（n = 198），brexucabtagene autoleucel显示ICANS的总体发生率高（61.2 %；95 % CI：54.2-67.8），其中较严重事件（32.9 %；95 % CI：26.7 %-39.7 %）略高于较轻事件（28.6 %；95 % CI：22.7 %-35.3 %）。
Chimeric antigen receptor (CAR) T-cell therapy, a form of adoptive immunotherapy, has expanded treatment options for various hematologic malignancies. However, CAR T therapy is associated with a range of side effects, including immune effector cell-associated neurotoxicity syndrome (ICANS), with variable incidence and severity.
To evaluate the incidence and characteristics of ICANS following CAR T therapy in different hematological diseases, with a focus on product-specific variations.
We searched PubMed, Embase, and Cochrane Library through 2/16/2024. Pooled incidence and 95 % confidence intervals (CIs) for ICANS (overall, more severe, and less severe) were estimated via a random-effects model. Separate meta-analyses were conducted for each lymphoma type - large B-cell lymphoma (LBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL).
Of 259 articles reviewed, 30 studies were meta-analyzed. Among LBCL patients, the incidence of ICANS appeared lower with tisagenlecleucel (16.5 %, 95 % CI: 12.9-20.9; n = 1108 patients) than with axicabtagene ciloleucel (45.6 %, 95 % CI: 39.6-51.7; n = 1579). In MM patients, the incidence appeared lower with ciltacabtagene autoleucel (10.4 %, 95 % CI: 5.2-19.9; n = 348) than with idecabtagene vicleucel (18.3 %; 95 % CI: 15.4-21.5; n = 631). For MCL patients (n = 198), brexucabtagene autoleucel showed a high overall incidence of ICANS (61.2 %; 95 % CI: 54.2-67.8), with more severe events (32.9 %; 95 % CI: 26.7 %-39.7 %) slightly exceeding less severe ones (28.6 %; 95 % CI: 22.7 %-35.3 %).
Tisa-cel and cilta-cel showed a more favorable ICANS safety profile in LBCL and MM patients, respectively, while brexu-cel showed a higher ICANS incidence in MCL patients. Further comparative studies are needed to adjust for treatment-related confounders.
MEMBER ACCOUNT
登录成功会直接打开下一页。
